The number of older people in the world is increasing, and this is having a positive impact on the market. In 2016, the Population Reference Bureau predicted that by 2060, there will be 98 million Americans aged 65 and older. The United Nations also estimates that by 2050, Asia will be home to around 857,040 older individuals. Globally, in 2018, there were approximately 962 million people aged 60 or over, making up 13% of the total global population. This aging population contributes to the growth of the anti-aging drugs market, as the demand for these drugs increases with age-related skin issues like wrinkles.
The demand for facial aesthetic treatments, products, and services is on the rise worldwide. These products offer benefits to the skin without the need for major surgeries, making them popular among patients. The increasing number of medical aesthetic practices, including medspas, has made these procedures more accessible and contributed to their growing popularity.
Developing regions, particularly in Asia, such as China, India, and South Korea, are witnessing a substantial demand for anti-aging methods. These countries play a significant role in the global anti-aging drugs market and are expected to remain the largest national markets in the region. South Korea, in particular, is experiencing significant growth, driven by widespread acceptance of cosmetic procedures, strong media influence, and affordable product prices. South Korea has also become a major destination for cosmetic tourism.
Corporate agreements are also playing a role in boosting the market in the Australian region. For example, Ipsen and Galderma have entered into a five-year exclusive agreement allowing Galderma to distribute and market Dysport for aesthetic use in Australia. This type of collaboration helps expand the market reach and availability of aesthetic products in different regions.
In summary, the increasing geriatric population is a key factor influencing the growth of the market. The demand for facial aesthetic treatments is also on the rise globally, with developing regions like Asia contributing significantly. Corporate agreements further contribute to market growth by facilitating the distribution and marketing of aesthetic products in various regions. The combination of these factors is driving the expansion of the anti-aging and facial aesthetics market worldwide.
Report Attribute/Metric | Details |
---|---|
Segment Outlook | Drug Class, Application, And Region |
The Anti-Ageing Drugs Market size was valued at USD 44.9 billion in 2023 and is projected to grow from USD 47.99 Billion in 2024 to USD 83.39 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 6.9% during the forecast period (2024 - 2032). The rising ageing population, high levels of disposable incomes, and the influence of lifestyle industry and rising awareness are driving the market growth.
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
The strong and rapid increase in the world's elderly population is creating a wide range of possibilities for the development of anti-aging drugs. The growing elderly population serves as a target market for anti-aging medications, propelling the market forward. According to the World Health Organization (WHO), the number of people over 60 years old in the population is expected to double by 2050, reaching 22 percent from 12 percent in 2015.
In addition, the desire among the elderly to stay young and healthy has also grown stronger as a result of the lifestyle and fashion sectors' expanding influence. Moreover, people of all ages are becoming more interested in anti-aging medications as a consequence of rising aesthetic standards. Therefore, the use of anti-aging products has become more popular among the aging population, and this increased awareness is causing the anti-aging drugs market to experience substantial growth in the coming years.
The anti-ageing drugs market segmentation, based on drug class, includes serums and supplements, antioxidants and enzymes, stem cells, and drugs. The serums and supplements segment held the majority share in 2022 in the anti-ageing drugs market revenue. This is due to rise in consumer awareness about age-related skin problems such as fine lines, wrinkles, and skin dullness and increase in inclination toward spending on products that help them proclaim their skin's youthfulness. Furthermore, the majority of skin care and cosmetics products, including many other skin care and cosmetics products, are changing their design. In the upcoming years, the anti-aging serums market is anticipated to follow pace.
November 2019:Estee Lauder Inc. (US) acquired Have & Be Co. Ltd. (South Korea). The acquisition is to help further strengthen the Estée Lauder Companies’ leadership position in skin care and will especially help expand the Company’s consumer reach in Asia/Pacific, North America, the UK, and travel retail.
Figure 2: ANTI-AGEING DRUGS MARKET, BY DRUG CLASS, 2023 & 2032 (USD BILLION)
Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review
The anti-ageing drugs market segmentation, based on application, includes skin and hair, skeletal and muscles, age related disorders, and others. The skin and hair segment held the majority share in 2022 in the anti-ageing drugs market revenue. This is due to growing interest in the effectiveness of regimens and routines, increasing demand for health-promoting and self-care products. Additionally, in 2021, skincare held the top spot, making up about 41% of the worldwide market. Another 22% went to haircare products, and about 16% went to cosmetics. One of the most lucrative product categories is skincare, with sales expected to reach 188 billion dollars in 2026. About 35% of the industry as of 2021 was accounted for by the North-Asian region.
June 2021: Procter & Gamble (US) launched Nervive, a new lineup of dietary supplements developed with over 50 years of nerve care expertise, to promote healthy nerves in the US.
By Region, the study segments the market into North America, Europe, Asia-Pacific, and the Rest of the World. The North America anti-ageing drugs market accounted for largest market share. This is attributed to high disposable income, increasing awareness of aesthetic looks, and increasing awareness about ageing signs in the region. According to U.S. Census Bureau, around 83.1 million are millennial present in United Nation which represent more than one quarter of the national population. Therefore, these factors have collectively led to the expansion of anti-ageing drugs market in the region.
Further, the major countries studied are the U.S., Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 3: ANTI-AGEING DRUGS MARKET SHARE BY REGION, 2023 & 2032 (USD BILLION)
Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review
Europe anti-ageing drugs market is expected to account for the second-largest market share due to the present of huge ageing population in the region. Further, the Germany anti-ageing drugs market is expected to hold 3rd place for the market share, and the UK anti-ageing drugs market is expected to fastest-growing market, and which is in the 4th place in the European region. Furthermore, France anti-ageing drugs market will hold the 5th place for the market share.
The Asia-Pacific anti-ageing drugs market is expected to grow at a steady pace from 2024 to 2032. This is due to the changing lifestyle cross the region. Moreover, China anti-ageing drugs market is expected to hold the largest market share, and India anti-ageing drugs market is expected fastest-growing market in the Asia-Pacific region.
Furthermore, China continues to place among the top countries that support the growth of the skincare and cosmetics industry, including anti-aging, sun care, and skin lightening products, in terms of both production and consumption. Growing senior populations across the country will increase demand for anti-aging medications is anticipated to fuel the growth for the anti-ageing drugs market.
The Rest of the World includes the Middle East, Africa, and Latin America. This segment is projected to hold the least share in the anti-ageing drugs market. Moreover, the Middle East North Africa (MENA) and the rest of the world region is expected to see limited growth owing to abject poverty, corruption, low economic growth, unstable political conditions.
Anti-Ageing Drugs Key Market Players & Competitive Insights
The anti-ageing drugs market is characterized by the presence of many global, regional, and local vendors catering to the demand created by research scientists and pharmaceutical and biotechnology companies operating in the industry. The market comprises tier-1, tier-2, and local players. The tier-1 and tier-2 players have reach across the globe with diverse product portfolios. Companies such as Merz Pharma (Germany), Procter & Gamble (US), Nu Skin (US), and BIOTIME Inc (US) the anti-ageing drugs market due to product differentiation, financial stability, strategic developments, and diversified regional presence. The players are focused on investing in research and development. Furthermore, they adopt strategic growth initiatives, such as expansion, product launches, joint ventures, and partnerships, to strengthen their market position and capture a large customer base.
One of the primary business strategies adopted by manufacturers in the anti-ageing drugs industry to benefit clients and expand the anti-ageing drugs market sector is to manufacture locally to reduce operating costs.
The Procter & Gamble Company (Procter & Gamble) manufactures, markets, distributes, and sells consumer packaged goods across the globe. The company operates through five business segments, namely, grooming, beauty, healthcare, fabric & home care, and baby, feminine, and family care. Its hair care category under the beauty segment includes shampoos, conditioners, and hair styling products. It sells its products through mass merchandisers, drug stores, department stores, specialty beauty stores, high-frequency stores, and pharmacies, among others. For instance, in June 2020, Elysium Health Inc. (US) introduced SIGNALTM, a unique combination of the most potent SIRT3 activators and the most direct NAD+ precursor, NMN, to support healthy mitochondrial function and promote a healthy metabolism by replenishing essential metabolic factors lost with aging.
Also, Merz Pharma (Germany) is a aesthetic and neurotoxin company that has strong research and development capabilities. Its aesthetic products are renowned for their extraordinary quality and outstanding results. It aims to achieve and discover the needs of specialists and work in line to help patients achieve their desired results. Its skincare product portfolio offers treatments such as scars, acne, hair loss, and fungal diseases. It also operates in fields such as neurology, Over the Counter (OTC) medicines, and dietary supplements. It has a presence in more than 34 countries and offers its products in around 90 countries.
Key Companies in the Anti-Ageing Drugs Market include
September 2022:La Roche-Posay (UK) launches new effaclar salicylic acid acne treatment serum with added anti-aging benefits.la roche-posay's new effaclar salicylic acid acne treatment serum is specifically formulated to target adult acne, as the clinical signs differ from adolescent acne in how they develop, where they show up, and the type of acne that occurs.
February 2020:DermaFix (South Africa) introduced Dermafix Acc Retinol +. DermaFix ACC Retinol + stimulates the fibroblasts helping to thicken the dermis for firmer and younger-looking skin. This revolutionary serum, incorporating advanced Vitamin C, resurfaces the skin whilst offering superior skin revitalization.
May 2022:La Roche-Posay (UK) launched new anti-aging face sunscreen SPF 70 daily anti-aging face sunscreen clinically tested on all skin types. The Anthelios UV Correct SPF 70 Daily Anti-Aging Face Sunscreen is formulated with Cellox-B3 Shield technology to correct and protect the skin from signs of sun damage.
January 2023:La Roche-Posay (UK) launched new anti-aging face sunscreen SPF 70 daily anti-aging face sunscreen clinically tested on all skin types. The Anthelios UV Correct SPF 70 Daily Anti-Aging Face Sunscreen is formulated with Cellox-B3 Shield technology to correct and protect the skin from signs of sun damage.
Anti-Ageing Drugs Regional Outlook
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)